Alaina Ritter and Kathryn DeSear coauthored a joint IDGM/Pharm paper that was just published in Cureus!
Abstract:
“Prosthetic joint infection (PJI) remains one of the most serious complications of prosthetic joint implantation. For patients with PJI managed with debridement, antibiotics, and implant retention (DAIR) surgical approach, two to six weeks of targeted intravenous antibiotics plus rifampin is typically recommended. Subsequently, rifampin plus a second oral antibiotic is given for a total of three versus six months for hip and knee arthroplasty infections, respectively. The goal of our study was to evaluate whether adjunctive rifampin affects treatment outcomes in patients with staphylococcal PJI.”
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC12681345/
